San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Protego Biopharma is raising $51,047,342.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Richard Labaudiniere played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Protego Biopharma
Protego Biopharma focuses on developing therapeutics and companion diagnostics targeting protein misfolding diseases.

To learn more about Protego Biopharma, visit http://protegobiopharma.com/

Contact:
Richard Labaudiniere, Chief Executive Officer
858-242-1518
https://www.linkedin.com/in/richard-labaudiniere-2287a05/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved